Trial Profile
Phase II study of neoadjuvant erlotinib in patients with stage III-N2 non-small cell lung cancer with EGFR mutations
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2014
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Jan 2014 New trial record